Cargando…

Hospitalization and medical cost of patients with elevated serum N-terminal pro-brain natriuretic peptide levels

BACKGROUND: Patients with heart failure (HF) are reportedly at high risk for ‘all-cause’ re-hospitalization. A biomarker for HF, N-terminal pro-brain natriuretic peptide (NT-proBNP), enables to simply detect patients with possible HF (pHF). We examined the hospitalization and medical cost of Japanes...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitagawa, Toshiro, Oda, Noboru, Mizukawa, Mariko, Hidaka, Takayuki, Naka, Makiko, Nakayama, Susumu, Kihara, Yasuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5755927/
https://www.ncbi.nlm.nih.gov/pubmed/29304158
http://dx.doi.org/10.1371/journal.pone.0190979
_version_ 1783290659554197504
author Kitagawa, Toshiro
Oda, Noboru
Mizukawa, Mariko
Hidaka, Takayuki
Naka, Makiko
Nakayama, Susumu
Kihara, Yasuki
author_facet Kitagawa, Toshiro
Oda, Noboru
Mizukawa, Mariko
Hidaka, Takayuki
Naka, Makiko
Nakayama, Susumu
Kihara, Yasuki
author_sort Kitagawa, Toshiro
collection PubMed
description BACKGROUND: Patients with heart failure (HF) are reportedly at high risk for ‘all-cause’ re-hospitalization. A biomarker for HF, N-terminal pro-brain natriuretic peptide (NT-proBNP), enables to simply detect patients with possible HF (pHF). We examined the hospitalization and medical cost of Japanese patients detected by an elevated serum NT-proBNP, and also evaluated the effects of institutional team approaches for HF on their all-cause hospitalizations. METHODS: We retrospectively extracted all adult patients with serum NT-proBNP ≥400 pg/ml measured between January and March 2012 in Hiroshima University Hospital as pHF-positive patients. We studied their all-cause hospitalization records during the past 3-year period. We also extracted all pHF-negative patients with NT-proBNP <400 pg/ml and studied as well. In the pHF-positive patients followed for 3 years after starting interprofessional team approaches to prevent the onset and exacerbation of HF in the hospital, we compared the hospitalization and medical cost between the 3-year periods before and after the start of the team approaches. RESULTS: We enrolled 432 pHF-positive and 485 pHF-negative patients with one or more hospitalization records. Compared to the pHF-negative patients, the pHF-positive patients had longer total hospitalization days (median [interquartile range], 30 [13–58] versus. 18 [8–39], p <0.0001) and higher total medical cost for hospitalizations (2.42 [1.07–5.08] versus. 1.80 [0.79–3.65] million yen, p <0.0001). A subset of 303 pHF-positive patients was followed for 3 years after starting the team approaches, and we found that both total hospitalization days (30 [13–57] to 8 [0–31]) and medical cost for hospitalizations (2.59 [1.37–5.05] to 0.76 [0–2.38] million yen) showed marked reduction in them. CONCLUSIONS: Patients with an elevated serum NT-proBNP have longer hospitalizations and higher costs for all-cause hospitalizations than those without. Institutional team approaches for HF may reduce them.
format Online
Article
Text
id pubmed-5755927
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-57559272018-01-26 Hospitalization and medical cost of patients with elevated serum N-terminal pro-brain natriuretic peptide levels Kitagawa, Toshiro Oda, Noboru Mizukawa, Mariko Hidaka, Takayuki Naka, Makiko Nakayama, Susumu Kihara, Yasuki PLoS One Research Article BACKGROUND: Patients with heart failure (HF) are reportedly at high risk for ‘all-cause’ re-hospitalization. A biomarker for HF, N-terminal pro-brain natriuretic peptide (NT-proBNP), enables to simply detect patients with possible HF (pHF). We examined the hospitalization and medical cost of Japanese patients detected by an elevated serum NT-proBNP, and also evaluated the effects of institutional team approaches for HF on their all-cause hospitalizations. METHODS: We retrospectively extracted all adult patients with serum NT-proBNP ≥400 pg/ml measured between January and March 2012 in Hiroshima University Hospital as pHF-positive patients. We studied their all-cause hospitalization records during the past 3-year period. We also extracted all pHF-negative patients with NT-proBNP <400 pg/ml and studied as well. In the pHF-positive patients followed for 3 years after starting interprofessional team approaches to prevent the onset and exacerbation of HF in the hospital, we compared the hospitalization and medical cost between the 3-year periods before and after the start of the team approaches. RESULTS: We enrolled 432 pHF-positive and 485 pHF-negative patients with one or more hospitalization records. Compared to the pHF-negative patients, the pHF-positive patients had longer total hospitalization days (median [interquartile range], 30 [13–58] versus. 18 [8–39], p <0.0001) and higher total medical cost for hospitalizations (2.42 [1.07–5.08] versus. 1.80 [0.79–3.65] million yen, p <0.0001). A subset of 303 pHF-positive patients was followed for 3 years after starting the team approaches, and we found that both total hospitalization days (30 [13–57] to 8 [0–31]) and medical cost for hospitalizations (2.59 [1.37–5.05] to 0.76 [0–2.38] million yen) showed marked reduction in them. CONCLUSIONS: Patients with an elevated serum NT-proBNP have longer hospitalizations and higher costs for all-cause hospitalizations than those without. Institutional team approaches for HF may reduce them. Public Library of Science 2018-01-05 /pmc/articles/PMC5755927/ /pubmed/29304158 http://dx.doi.org/10.1371/journal.pone.0190979 Text en © 2018 Kitagawa et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Kitagawa, Toshiro
Oda, Noboru
Mizukawa, Mariko
Hidaka, Takayuki
Naka, Makiko
Nakayama, Susumu
Kihara, Yasuki
Hospitalization and medical cost of patients with elevated serum N-terminal pro-brain natriuretic peptide levels
title Hospitalization and medical cost of patients with elevated serum N-terminal pro-brain natriuretic peptide levels
title_full Hospitalization and medical cost of patients with elevated serum N-terminal pro-brain natriuretic peptide levels
title_fullStr Hospitalization and medical cost of patients with elevated serum N-terminal pro-brain natriuretic peptide levels
title_full_unstemmed Hospitalization and medical cost of patients with elevated serum N-terminal pro-brain natriuretic peptide levels
title_short Hospitalization and medical cost of patients with elevated serum N-terminal pro-brain natriuretic peptide levels
title_sort hospitalization and medical cost of patients with elevated serum n-terminal pro-brain natriuretic peptide levels
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5755927/
https://www.ncbi.nlm.nih.gov/pubmed/29304158
http://dx.doi.org/10.1371/journal.pone.0190979
work_keys_str_mv AT kitagawatoshiro hospitalizationandmedicalcostofpatientswithelevatedserumnterminalprobrainnatriureticpeptidelevels
AT odanoboru hospitalizationandmedicalcostofpatientswithelevatedserumnterminalprobrainnatriureticpeptidelevels
AT mizukawamariko hospitalizationandmedicalcostofpatientswithelevatedserumnterminalprobrainnatriureticpeptidelevels
AT hidakatakayuki hospitalizationandmedicalcostofpatientswithelevatedserumnterminalprobrainnatriureticpeptidelevels
AT nakamakiko hospitalizationandmedicalcostofpatientswithelevatedserumnterminalprobrainnatriureticpeptidelevels
AT nakayamasusumu hospitalizationandmedicalcostofpatientswithelevatedserumnterminalprobrainnatriureticpeptidelevels
AT kiharayasuki hospitalizationandmedicalcostofpatientswithelevatedserumnterminalprobrainnatriureticpeptidelevels